ACE.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:29):

Stats
Today's Volume	279 835
Average Volume	212 238
Market Cap	357.83M
EPS	SEK0 ( 2024-02-08 )
Next earnings date	( SEK-0.400 ) 2024-05-15
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-3.27
ATR14	SEK0.0680 (0.64%)

Volume Correlation

Long: 0.03 (neutral)

Short: 0.57 (weak)

Signal:(57.359) Neutral

Ascelia Pharma AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ascelia Pharma AB (publ) Correlation - Currency/Commodity

-0.27
( neutral )

-0.16
( neutral )

0.00
( neutral )

0.07
( neutral )

0.55
( weak )

0.08
( neutral )

Ascelia Pharma AB (publ) Financials

Annual	2023
Revenue:	SEK0
Gross Profit:	SEK-1.05M (0.00 %)
EPS:	SEK-3.24

Q4	2023
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-0.310

Q3	2023
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-0.630

Q2	2023
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-1.190

Financial Reports:

No articles found.

Ascelia Pharma AB (publ)

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.